Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

Non-alcoholic steatohepatitis (NASH) is a condition characterized by accumulation of fat, inflammation and injury in liver cells in people who consume little or no alcohol. It is the progressive ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

Inventiva (NASDAQ:IVA – Get Free Report) is projected to issue its quarterly earnings data before the market opens on ...

† NASHTest is a combination of age, gender, height, weight serum triglycerides, cholesterol, α2-macroglobulin, apolipoprotein A1, haptoglobin, γ ...

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

Galmed (GLMD) announced the grant of a new patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of ...

For the first time, the European Medicines Agency has recognized AI software for the diagnosis of fatty liver hepatitis as ...

The advent of artificial intelligence (AI) in healthcare is creating waves of innovation, transforming traditional medical practices. One of the ...

The doctor explained that beside alcohol consumption and hepatitis, hypertension can contribute significantly to liver fibrosis.

PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...

Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a ...